Have You Tested Positive for Coronavirus (COVID-19) In The Last Two Days?

Are you interested in being in a Stanford research study of an investigational new treatment?

Please contact us as soon as possible after getting a positive Covid-19 test result as the study must start within 72 hours of the test being performed.

Clinical Trials

Favipiravir Study for Coronavirus

Active — Recruiting

Have you tested positive for coronavirus (COVID-19) in the last two days? Are you interested in being in a Stanford study of an investigational treatment for COVID-19?

Lambda COVID-19 Study

Active — Not Recruiting

We have recruited participants who have tested for positive for COVID-19 with mild symptoms who can be treated as outpatients. In addition to one dose of Peginterferon Lambda-1a or placebo, patients will receive serial testing to detect length of viral shedding in respiratory secretions, monitoring of clinical signs and symptoms, and will receive compensation for each visit. Participants must be 18-64 years of age and in generally good health.

In the News

Stanford researchers test oral COVID-19 treatment for mild cases
A team of Stanford researchers have begun a clinical trial on Favipiravir, an antiviral drug that aims to reduce symptoms of COVID-19

Stanford Doctor Discusses New Coronavirus Trial
Dr. Prasanna Jagannathan talks with Raj Mathai of NBC Bay Area about the trial and the treatment.

Stanford Researchers Looking into a New Drug to Treat Milder Coronavirus Cases
KCBS news anchor Susan Leigh Taylor spoke with Dr. Upi Singh, co-leader of the study and professor of infectious diseases at the Stanford Medical School.

Interferon emerges as potential treatment for COVID-19
Upinder Singh tells The Globe and Mail Canada that evidence the treatment clears the virus sooner than would may not only improve outcomes for patients but reduce transmission in the community.

Stanford Medicine researchers lead clinical trial of interferon-lambda for COVID-19
Scientists at Stanford Medicine are investigating whether a molecule called interferon-lambda can help people with mild cases of COVID-19 feel better and reduce their transmission of the disease-causing virus.